We recently showed that human melanoma cells release FGF-2, which induces TAB to secrete IGF-1, a source of acquired drug resistance of melanoma cells to mitogen-activated protein kinase (MAPK) inhibitors13. This evidence concerns the gene IGF1 and melanoma.